Reactogenicity following receipt of mRNA-based COVID-19 vaccines
J Chapin-Bardales, J Gee, T Myers - Jama, 2021 - jamanetwork.com
In December 2020, 2 mRNA-based COVID-19 vaccines (Pfizer-BioNTech and Moderna)
were granted Emergency Use Authorization by the US Food and Drug Administration as 2-
dose series and recommended for use by the Advisory Committee on Immunization
Practices. 1-3 In late February 2021, the US Food and Drug Administration granted
Emergency Use Authorization for a third COVID-19 vaccine, a single-dose adenovirus vector-
based vaccine from Janssen (Johnson & Johnson). In clinical trials of the mRNA-based 2 …
were granted Emergency Use Authorization by the US Food and Drug Administration as 2-
dose series and recommended for use by the Advisory Committee on Immunization
Practices. 1-3 In late February 2021, the US Food and Drug Administration granted
Emergency Use Authorization for a third COVID-19 vaccine, a single-dose adenovirus vector-
based vaccine from Janssen (Johnson & Johnson). In clinical trials of the mRNA-based 2 …